חיפוש מתקדם
Journal of Clinical Investigation
Stalmans, I., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Ng, Y.-S., Schepens Eye Research Institute, Department of Pathology and Ophthalmology, Harvard Medical School, Boston, MA, United States
Rohan, R., Children's Hospital, Harvard Medical School, Boston, MA, United States
Fruttiger, M., Wolfson Institute for Biomedical Research, University College London, London, United Kingdom
Bouché, A., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Ÿuce, A., Third Department of Internal Medicine, Justus Liebig University, Giessen, Germany
Fujisawa, H., Department of Molecular Biology, Nagoya University, Nagoya, Japan
Hermans, B., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Shani, M., Institute of Animal Science, Volcani Center, Bet Dagan, Israel
Jansen, S., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Hicklin, D., Department of Immunology, ImClone Systems Incorporated, New York, NY, United States
Anderson, D.J., Division of Biology, Howard Hughes Medical Institute, California Institute of Technology, Pasadena, CA, United States
Gardiner, T., Ophthalmology and Vision Science, Institute of Clinical Science, Queen's University, Belfast, Ireland
Hammes, H.-P., Medical Department, University Clinic, Mannheim, Germany
Moons, L., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Dewerchin, M., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Collen, D., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Carmeliet, P., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium, Center for Transgene Technology and Gene Therapy, Catholic University Leuven, Campus Gasthuisberg, Herestraat 49, B-3000, Leuven, Belgium
D'Amore, P.A., Schepens Eye Research Institute, Department of Pathology and Ophthalmology, Harvard Medical School, Boston, MA, United States
The murine VEGF gene is alternatively transcribed to yield the VEGF120, VEGF164, and VEGF188 isoforms, which differ in their potential to bind to heparan sulfate and neuropilin-1 and to stimulate endothelial growth. Here, their role in retinal vascular development was studied in mice selectively expressing single isoforms. VEGF164/164 mice were normal, healthy, and had normal retinal angiogenesis. In contrast, VEGF120/120 mice exhibited severe defects in vascular outgrowth and patterning, whereas VEGF188/188 mice displayed normal venular outgrowth but impaired arterial development. It is noteworthy that neuropilin-1, a receptor for VEGF164, was predominantly expressed in retinal arterioles. These findings reveal distinct roles of the various VEGF isoforms in vascular patterning and arterial development in the retina.
פותח על ידי קלירמאש פתרונות בע"מ -
הספר "אוצר וולקני"
אודות
תנאי שימוש
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms
109
Stalmans, I., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Ng, Y.-S., Schepens Eye Research Institute, Department of Pathology and Ophthalmology, Harvard Medical School, Boston, MA, United States
Rohan, R., Children's Hospital, Harvard Medical School, Boston, MA, United States
Fruttiger, M., Wolfson Institute for Biomedical Research, University College London, London, United Kingdom
Bouché, A., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Ÿuce, A., Third Department of Internal Medicine, Justus Liebig University, Giessen, Germany
Fujisawa, H., Department of Molecular Biology, Nagoya University, Nagoya, Japan
Hermans, B., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Shani, M., Institute of Animal Science, Volcani Center, Bet Dagan, Israel
Jansen, S., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Hicklin, D., Department of Immunology, ImClone Systems Incorporated, New York, NY, United States
Anderson, D.J., Division of Biology, Howard Hughes Medical Institute, California Institute of Technology, Pasadena, CA, United States
Gardiner, T., Ophthalmology and Vision Science, Institute of Clinical Science, Queen's University, Belfast, Ireland
Hammes, H.-P., Medical Department, University Clinic, Mannheim, Germany
Moons, L., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Dewerchin, M., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Collen, D., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
Carmeliet, P., Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium, Center for Transgene Technology and Gene Therapy, Catholic University Leuven, Campus Gasthuisberg, Herestraat 49, B-3000, Leuven, Belgium
D'Amore, P.A., Schepens Eye Research Institute, Department of Pathology and Ophthalmology, Harvard Medical School, Boston, MA, United States
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms
The murine VEGF gene is alternatively transcribed to yield the VEGF120, VEGF164, and VEGF188 isoforms, which differ in their potential to bind to heparan sulfate and neuropilin-1 and to stimulate endothelial growth. Here, their role in retinal vascular development was studied in mice selectively expressing single isoforms. VEGF164/164 mice were normal, healthy, and had normal retinal angiogenesis. In contrast, VEGF120/120 mice exhibited severe defects in vascular outgrowth and patterning, whereas VEGF188/188 mice displayed normal venular outgrowth but impaired arterial development. It is noteworthy that neuropilin-1, a receptor for VEGF164, was predominantly expressed in retinal arterioles. These findings reveal distinct roles of the various VEGF isoforms in vascular patterning and arterial development in the retina.
Scientific Publication
You may also be interested in